No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic‐induced tardive dyskinesia; Human Psychopharmacology: Clinical and Experimental; Vol. 34, iss. 1

Bibliographic Details
Parent link:Human Psychopharmacology: Clinical and Experimental
Vol. 34, iss. 1.— 2019.— [e2685, 5 p.]
Corporate Author: Национальный исследовательский Томский политехнический университет Инженерная школа неразрушающего контроля и безопасности Отделение контроля и диагностики
Other Authors: Levchenko A. Anastasia, Vyalova N. M. Nataljya Mikhaylovna, Pozhidaev I. V. Ivan, Boyko A. S., Osmanova D. Z. Diana, Fedorenko O. Yu. Olga Yurievna, Semke A. V. Arkady Valentinovich, Bokhan N. A. Nikolay Aleksandrovich, Wilffert B. Bob, Loonen A. J. M. Anton, Ivanova S. A. Svetlana Aleksandrovna
Summary:Title screen
Objective. AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic‐induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic‐treated patients with schizophrenia. Methods. DNA samples from 449 patients from several Siberian regions (Russia) were genotyped, and the results were analyzed using chi‐squared tests and analyses of variance. Results. Antipsychotic‐induced TD was not associated with either of the tested functional polymorphisms (rs334558, rs1130214, and rs3730358). Conclusions. Despite regulation of AKT1 and GSK3B by DRD2, we found no evidence that these two kinases play a major role in the pathogenesis of antipsychotic‐induced TD. These results agree with previously published data and necessitate further exploration of other pathogenic mechanisms, such as neurotoxicity due to excessive dopamine metabolism.
Режим доступа: по договору с организацией-держателем ресурса
Language:English
Published: 2019
Subjects:
Online Access:https://doi.org/10.1002/hup.2685
Format: Electronic Book Chapter
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=659610

MARC

LEADER 00000naa0a2200000 4500
001 659610
005 20250321173240.0
035 |a (RuTPU)RU\TPU\network\28277 
035 |a RU\TPU\network\28156 
090 |a 659610 
100 |a 20190311d2019 k||y0rusy50 ba 
101 0 |a eng 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic‐induced tardive dyskinesia  |f A. Levchenko [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
330 |a Objective. AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic‐induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic‐treated patients with schizophrenia. Methods. DNA samples from 449 patients from several Siberian regions (Russia) were genotyped, and the results were analyzed using chi‐squared tests and analyses of variance. Results. Antipsychotic‐induced TD was not associated with either of the tested functional polymorphisms (rs334558, rs1130214, and rs3730358). Conclusions. Despite regulation of AKT1 and GSK3B by DRD2, we found no evidence that these two kinases play a major role in the pathogenesis of antipsychotic‐induced TD. These results agree with previously published data and necessitate further exploration of other pathogenic mechanisms, such as neurotoxicity due to excessive dopamine metabolism. 
333 |a Режим доступа: по договору с организацией-держателем ресурса 
461 |t Human Psychopharmacology: Clinical and Experimental 
463 |t Vol. 34, iss. 1  |v [e2685, 5 p.]  |d 2019 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a AKT1 
610 1 |a antipsychotics 
610 1 |a GSK3B 
610 1 |a pharmacogenetics 
610 1 |a schizophrenia 
610 1 |a tardive dyskinesia 
610 1 |a фармакогенетика 
610 1 |a шизофрения 
701 1 |a Levchenko  |b A.  |g Anastasia 
701 1 |a Vyalova  |b N. M.  |g Nataljya Mikhaylovna 
701 1 |a Pozhidaev  |b I. V.  |g Ivan 
701 1 |a Boyko  |b A. S. 
701 1 |a Osmanova  |b D. Z.  |g Diana 
701 1 |a Fedorenko  |b O. Yu.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1973-  |g Olga Yurievna  |3 (RuTPU)RU\TPU\pers\33861  |9 17450 
701 1 |a Semke  |b A. V.  |g Arkady Valentinovich 
701 1 |a Bokhan  |b N. A.  |g Nikolay Aleksandrovich 
701 1 |a Wilffert  |b B.  |g Bob 
701 1 |a Loonen  |b A. J. M.  |g Anton 
701 1 |a Ivanova  |b S. A.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1964-  |g Svetlana Aleksandrovna  |3 (RuTPU)RU\TPU\pers\33859 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Инженерная школа неразрушающего контроля и безопасности  |b Отделение контроля и диагностики  |3 (RuTPU)RU\TPU\col\23584 
801 2 |a RU  |b 63413507  |c 20190311  |g RCR 
856 4 |u https://doi.org/10.1002/hup.2685 
942 |c CF